Affordable Access

Access to the full text

Neuroimaging and Molecular Biomarkers for Dementia

Authors
  • Polyakova, T. A.1
  • Arablinsky, A. V.2
  • 1 Russian Medical Academy of Continuing Professional Education, Moscow, Russia , Moscow (Russia)
  • 2 Sechenov First Moscow Medical University (Sechenov University), Moscow, Russia , Moscow (Russia)
Type
Published Article
Journal
Neuroscience and Behavioral Physiology
Publisher
Springer US
Publication Date
Apr 26, 2019
Volume
49
Issue
4
Pages
406–412
Identifiers
DOI: 10.1007/s11055-019-00747-7
Source
Springer Nature
Keywords
License
Yellow

Abstract

The development of laboratory diagnostic and neuroimaging methods allows a number of biomarkers to be detected, improving the in-life diagnosis of a very diverse set of types of dementia (Alzheimer’s disease, Lewy body dementia, vascular dementia). Currently, molecular biomarkers in the cerebrospinal fluid (CSF) for detection of Alzheimer’s disease have the greatest diagnostic sensitivity and specificity. At the same time, structural changes detected on MRI scans are more significant for prognosticating the development of changes in the cognitive domain. Cerebral microbleeds provide an additional accessible marker increasing the diagnostic significance of leukoaraiosis and providing evidence of cerebral amyloid angiopathy or hypertensive microangiopathy, especially in cases of mixed pathology and severe cognitive deficit.

Report this publication

Statistics

Seen <100 times